In Brief: NeoPath
This article was originally published in The Gray Sheet
NeoPath: Redmond, Washington-based company issues retraction Feb. 9 for statements made in a Sept. 6, 1995 release comparing NeoPath's AutoPap 300QC automated cervical cytology reader with Neuromedical Systems, Inc.'s Papnet system ("The Gray Sheet" Oct. 9, 1995, p. 6). "FDA has determined" that a comparison of the two systems' "relative sensitivity" made in the Sept. 6 release "represents an unfair comparison of these two medical devices," NeoPath says, adding that the company "did not intend to suggest that a direct comparison between" AutoPap and Papnet "had been attempted"...
You may also be interested in...
Siemens Healthineers' product mix of diagnostics and imaging products meant it was in the middle of a very dynamic situation when COVID-19 struck.
The WHO’s new "living guideline" against remdesivir’s use in hospitalized patients notwithstanding, some key opinion leaders in India see a role for the antiviral, but underscore that COVID-19 is still in its infancy and all repurposed therapies for the disease still have a long way to go. They also see the US remdesivir studies as more robust.
Join us for a brief audio tour around the past week's major global biopharma industry developments, in this podcast version of Scrip's Five Must-Know Things.